Koss Olinger Consulting LLC Sells 10,300 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Koss Olinger Consulting LLC reduced its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 52.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 9,518 shares of the medical equipment provider’s stock after selling 10,300 shares during the period. Koss Olinger Consulting LLC’s holdings in Zimmer Biomet were worth $856,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in ZBH. M&T Bank Corp lifted its position in shares of Zimmer Biomet by 15,705.6% during the fourth quarter. M&T Bank Corp now owns 3,571,595 shares of the medical equipment provider’s stock valued at $321,158,000 after purchasing an additional 3,548,998 shares in the last quarter. Norges Bank bought a new position in shares of Zimmer Biomet during the fourth quarter valued at about $221,234,000. Dodge & Cox lifted its position in shares of Zimmer Biomet by 5.1% during the third quarter. Dodge & Cox now owns 23,216,173 shares of the medical equipment provider’s stock valued at $2,286,793,000 after purchasing an additional 1,118,710 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Zimmer Biomet by 276.6% during the second quarter. AQR Capital Management LLC now owns 1,300,593 shares of the medical equipment provider’s stock valued at $118,627,000 after purchasing an additional 955,284 shares in the last quarter. Finally, Capital International Investors lifted its position in shares of Zimmer Biomet by 11.5% during the third quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock valued at $743,749,000 after purchasing an additional 778,467 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Stifel Nicolaus decreased their price objective on shares of Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating for the company in a report on Wednesday, April 29th. JPMorgan Chase & Co. decreased their price objective on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a report on Wednesday, April 29th. Leerink Partners assumed coverage on shares of Zimmer Biomet in a report on Monday, April 13th. They set a “hold” rating and a $101.00 price objective for the company. Truist Financial restated a “hold” rating and set a $92.00 price objective (down from $98.00) on shares of Zimmer Biomet in a report on Wednesday, April 29th. Finally, Robert W. Baird set a $92.00 price objective on shares of Zimmer Biomet in a report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $102.70.

Zimmer Biomet Price Performance

ZBH opened at $82.46 on Friday. The company has a market capitalization of $15.95 billion, a price-to-earnings ratio of 21.42, a PEG ratio of 1.92 and a beta of 0.48. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50. The firm has a 50-day moving average price of $87.96 and a 200-day moving average price of $90.63. Zimmer Biomet Holdings, Inc. has a twelve month low of $79.12 and a twelve month high of $108.29.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, topping the consensus estimate of $1.86 by $0.23. The firm had revenue of $2.09 billion during the quarter, compared to the consensus estimate of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The company’s revenue was up 9.3% on a year-over-year basis. During the same quarter last year, the company earned $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.47 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Thursday, June 25th will be paid a $0.24 dividend. The ex-dividend date is Thursday, June 25th. This represents a $0.96 annualized dividend and a dividend yield of 1.2%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 24.94%.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 2,650 shares of Zimmer Biomet stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $94.66, for a total value of $250,849.00. Following the completion of the transaction, the senior vice president owned 10,224 shares in the company, valued at $967,803.84. This trade represents a 20.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.28% of the stock is owned by insiders.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.